Bezafibrate: An update of its pharmacology and use in the management of dyslipidaemia

Drugs

Volumn 52, Issue 5, 1996, Pages 725-753

  Goa, Karen L ^a   Barradell, Lee B ^a   Plosker, Greg L ^a  

^a ADIS INTERNATIONAL LIMITED   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BEZAFIBRATE; COLESTIPOL; COLESTYRAMINE; CYCLOSPORIN; FIBRINOGEN; FLUINDOSTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ANAPHYLAXIS; BLOOD GLUCOSE MONITORING; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DROWSINESS; DRUG EFFICACY; DYSLIPIDEMIA; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HEART SURGERY; HUMAN; HYPERTRIGLYCERIDEMIA; ISCHEMIC HEART DISEASE; KIDNEY DISEASE; LIBIDO; LIPID BLOOD LEVEL; MORBIDITY; MORTALITY; MYALGIA; PHARMACOECONOMICS; REVIEW; RHABDOMYOLYSIS; SKIN DISEASE;

EID: 0029825461     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-199652050-00008     Document Type: Review

References (187)

1. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Summary of the Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection. Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II). JAMA 1993; 269 (23): 3015-23
2. Monk JP, Todd PA, Bezafibrate: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia. Drugs 1987 Jun; 33: 539-76
3. Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med 1987 Nov 27; 83: 9-20
4. Shepherd J. Mechanism of action of fibrates. Postgrad Med J 1993; 69 Suppl. 1: S34-41
5. Homma Y, Ozawa H, Kobayashi T, et al. Effects of bezafibrate therapy on subfractions of plasma low-density lipoprotein and high-density lipoprotein, and on activities of lecithin:cholesterol acyltransferase and cholesteryl ester transfer protein in patients with hyperlipoproteinemia. Atherosclerosis 1994 Apr; 106: 191-201
6. Yano T, Kobori S, Sasahara T, et al. Effects of bezafibrate on cholesteryl ester transfer protein in type III hyperlipoproteinaemia with apo E phenotype E2/E2 [abstract no. 293]. Atherosclerosis 1994 Sep 15; 109: 199
7. Cosentini R, Blasi F, Trinchera M, et al. Inhibition of cholesterol biosynthesis in freshly isolated blood mononuclear cells from normolipidemic subjects and hypercholesterolemic patients treated with bezafibrate. Atherosclerosis 1989 Oct 3; 79: 253-5
8. Blasi F, Sommariva D, Cosentini R, et al. Bezafibrate inhibits HMG-CoA reductase activity in incubated blood mononuclear cells from normal subjects and patients with heterozygous familial hypercholesterolaemia. Pharmacol Res 1989 May-Jun; 21: 247-54
9. Stange EF, Fruhholz M, Osenbrugge M, et al. Bezafibrate fails to directly modulate HMG-CoA reductase or LDL catabolism in human mononuclear cells. Eur J Clin Pharmacol 1991 Feb; 40 Suppl. 1: 37-40
10. Chrisp P, Lewis NJW, Milne RJ. Simvastatin: a pharmacoeconomic evaluation of its cost-effectiveness in hypercholesterolaemia and prevention of coronary heart disease. PharmacoEconomics 1992 Feb; 1: 124-45
11. Fredrickson DS, Levy RI, Lee RS. Fat transport in lipoproteins - an integrated approach to mechanisms and disorders. N Engl J Med 1967; 276 (1): 34-45, 94-103, 148-9, 215-25, 273-81
12. Kleinman Y, Oschry Y, Eisenberg S. Abnormal regulation of LDL receptor activity and abnormal cellular metabolism of hypertriglyceridaemic low density lipoprotein: normalization with bezafibrate therapy. Eur J Clin Invest 1987 Dec; 17: 538-43
13. Eisenberg S. Effects of fibrates on the altered lipoprotein system in hypertriglyceridemia. In: Catapano AL et al., editors. Drugs affecting lipid metabolism. The Netherlands: Kluwer Academic Publishers and Fondazione Giovanni Lorenzini, 1993: 477-82
14. Cosentini R, Blasi F, Sommariva D, et al. Effects of bezafibrate on biosynthesis of cholesterol and on degradation of native and acetylated low-density lipoproteins in incubated human monocytes. Drugs Exp Clin Res 1992; 18 (6): 245-50
15. Series JJ, Caslake MJ, Kilday C, et al. Effect of combined therapy with bezafibrate and cholestyramine on low-density lipoprotein metabolism in type IIa hypercholesterolemia. Metabolism 1989 Feb; 38: 153-8
16. Schwandt P. Fibrates and triglyceride metabolism. Eur J Clin Pharmacol 1991; 40 Suppl. 1: S41-3
17. Nakandakare E, Garcia RC, Rocha JC, et al. Effects of simvastatin, bezafibrate and gemfibrozil on the quantity and composition of plasma lipoproteins. Atherosclerosis 1990 Dec; 85: 211-7
18. Naruszewicz M, Mirkiewicz E, Klosiewicz-Latoszek L. Modification of low density lipoproteins from hypertriglyceridemic patients by macrophages in vitro and the effect of bezafibrate treatment. Atherosclerosis 1989 Oct 3; 79: 261-5
19. Naito M, Hayashi T, Iguchi A. New approaches to the prevention of atherosclerosis. Drugs 1995; 50 (3): 440-53
20. Kobayashi J, Takahashi K, Tashiro J, et al. Effects of treatment with bezafibrate on lipoprotein lipase activity and mass in patients with hypertriglyceridemia. Arzneimittel Forschung 1994 Feb; 44: 145-8
21. Saku K, Sasaki J, Arakawa K. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and post-heparin lipolytic activities in patients with type IV and type V hypertriglyceridemia. Clin Ther 1989 May-Jun; 11: 331-9
22. Stahlberg D. Effects of bezafibrate - a hypolipidemic drug. Cardiovasc Drug Rev 1992; 10 (3): 259-79
23. O'Connor P, Feely J, Shepherd J. Lipid lowering drugs. BMJ 1990 Mar 10; 300: 667-72
24. Sethi S, Gould BJ, Lovegrove JA, et al. Bezafibrate increases lipoprotein lipase activity and improves postprandial apolipoprotein B-48 metabolism in non-insulin dependent diabetes mellitus [abstract]. Atherosclerosis 1995 Jun; 115 Suppl.: S53
25. Smuts CM, Weich HKH, Weight MJ, et al. Free cholesterol concentrations in the high-density lipoprotein subtraction-3 as a risk indicator in patients with angiograpically documented coronary artery disease. Coron Artery Dis 1994 Apr; 5: 331-8
26. Sommariva D, Tirrito M, Bonfiglioli D, et al. Long-term effects of bezafibrate and of a bezafibrate and cholestyramine combination on lipids and lipoprotein lipids in type IIa hypercholesterolaemic patients. Int J Clin Pharmacol Res 1986; 6: 249-53
27. Saku K, Zhang B, Jimi S, et al. High-density lipoprotein and apolipoprotein A-I deficiency induced by combination therapy with probucol and bezafibrate. Eur J Clin Pharmacol 1995; 48 (3-4): 209-15
28. Kashyap MI, Saku K. HDL metabolism in HDL deficiency associated with familial hypertriglyceridaemia: effect of gemfibrozil. Adv Exp Med Biol 1991; 285: 233-6
29. Greten H, Beil FU, Schneider J, et al. Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate. Am J Med 1994 Jun 6; 96 Suppl. 6A: 55S-63S
30. Bimmermann A, Boerschmann C, Schwartzkopff W, et al. Effective therapeutic measures for reducing lipoprotein (a) in patients with dyslipidemia. Lipoprotein (a) reduction with sustained-release bezafibrate. Curr Ther Res 1991 Apr; 49: 635-43
31. Klosiewicz-Latoszek L, Szostak WB. Comparative studies on the influence of different fibrates on serum lipoproteins in endogenous hyperlipoproteinaemia. Eur J Clin Pharmacol 1991 Jan; 40: 33-41
32. Avogaro P, Bittolo BG, Cazzolato G, et al. A cross-over controlled study on beclofibrate versus bezafibrate in the treatment of type IIb hyperlipoproteinaemia. Drugs Exp Clin Res 1989 Jun-Jul; 15: 325-33
33. Schulzeck P, Bojanovski M, Jochim A, et al. Comparison between simvastatin and bezafibrate in effect on plasma lipoproteins and apolipoproteins in primary hypercholesterolaemia. Lancet 1988 Mar 19; 1: 611-3
34. Weisweiler P. Effects of bezafibrate and gemfibrozil on serum lipoproteins in primary hypercholesterolemia. Arzneimittel Forschung 1988 Jul; 38: 925-7
35. Hanefeld M, Lang PD, Fischer S, et al. Effects of a bezafibrate sustained release formulation on plasma lipoproteins in patients with hypercholesterolemia. Importance of timing of tablet intake for efficacy. Arzneimittel Forschung 1988 Dec; 38: 1835-7
36. Branchi A, Rovellini A, Sommariva D. Differential effects of simvastatin and bezafibrate on apolipoprotein-defined high-density lipoprotein subfractions in patients with hypercholesterolemia. Curr Ther Res 1996 Jan; 57 (1): 26-32
37. Branchi A, Rovellini A, Sommariva D. Effect of bezafibrate on HDL with apo A-I and apo A-II and on HDL with apo A-I without apo A-II in hyperlipidaemic patients. Int J Clin Pharmacol Res 1995; XV (4): 153-8
38. Klosiewicz-Latoszek L, Nowicka G, Szostak WB, et al. Influence of bezafibrate and colestipol on LDL-cholesterol. LDL-apolipoprotein B and HDL-cholesterol in hyperlipoproteinaemia. Atherosclerosis 1987 Feb; 63: 203-9
39. Lang PD. Bezafibrate in the treatment of hyperlipidemia. Bol Asoc Med PR 1989 Feb; 81: 59-60
40. Ikeuchi R, Sakuma N, Hibino T, el al. Increased serum triglyceride clearance, unchanged cholesteryl ester transfer protein activity, and elevated HDL cholesterol during treatment of hypertriglyceridemia with bezafibrate. Curr Ther Res 1994 Oct; 55: 1223-31
41. Spinler SA, Cziraky MJ. Lipoprotein(a): physiologic function, association with atherosclerosis, and effects of lipid-lowering drug therapy. Ann Pharmacother 1994 Mar; 28: 343-51
42. Branchi A, Rovellini A, Fiorenza AM, et al. Effects of bezafibrate and of 2 HMG-CoA reductase inhibitors on lipoprotein (a) level in hypercholesterolemic patients. Int J Clin Pharmacol Ther 1995 Jun; 33: 345-50
43. Maggi FM, Biasi GM, Calapano AL. Reduction of Lp(a) plasma levels by bezafibrate. Atherosclerosis 1993 Apr; 100: 127-8
44. Pazzucconi F, Mannucci L, Mussoni L, et al. Bezafibrate lowers plasma lipids, fibrinogen and platelet aggregability in hypertriglyceridaemia. Eur J Clin Pharmacol 1992 Sep; 43: 219-23
45. Montigny M, Riberdy R, Davignon J. Comparison of three fibric acid derivatives in hypertriglyceridemic patients, effect on Lp(a) levels [abstract no. 230]. Atherosclerosis 1994 Sep 15; 109: 317
46. Mollerach M, Bartomeo A, Bignone I, et al. Effects of bezfibrate (Bz) on Lp(a) and plasma fibrinogen (Fb) in non insulin dependent diabetic patients (NIDDM) [abstract no. 08A5PP0457]. Presented at the 15th International Diabetes Federation Congress (p. 268).
47. Perez-Jimenez F, Hidalgo L, Zambrana JL, et al. Comparison of lovastatin and bezafibrate on lipoprotein(a) plasma levels in cardiac transplant recipients. Am J Cardiol 1995 Mar 15; 75: 648-50
48. Barbir M, Hunt B, Kushwaha S, et al. Maxepa versus bezafibrate in hyperlipidemic cardiac transplant recipients. Am J Cardiol 1992 Dec 15; 70: 1596-601
49. Barbir M, Hunt BJ, Galloway D, et al. A randomized pilot trial of low-dose combination lipid-lowering therapy following coronary artery bypass grafting. Clin Cardiol 1994 Feb; 17: 59-64
50. Sirtori CR, Colli S. Influences of lipid-modifying agents on hemostasis. Cardiovasc Drugs Ther 1993 Nov; 7: 817-23
51. Schonfeld G. The effects of fibrates on lipoprotein and hemostatic coronary risk factors. Atherosclerosis 1994 Dec; 111: 161-74
52. Meade TW. Fibrinogen in ischaemic heart disease. Eur Heart J 1995; 16 Suppl. A: 31-5
53. Ernst E, Resch KL. Fibrinogen as a cardiovascular risk factor: a meta-analysis and review of the literature. Ann Intern Med 1993; 118: 956-63
54. Smith EB. Fibrinogen and atherosclerosis. Wien Klin Wochenschr 1993; 105 (15): 417-24
55. Caimi G, Francavilla G, Romano A, et al. Blood rheology changes during bezafibrate treatment. Br J Clin Pract 1988 Nov; 42: 456-8
56. Niort G, Bulgarelli A, Cassader M, et al. Effect of short-term treatment with bezafibrate on plasma fibrinogen, fibrinopeptide A, platelet activation and blood filterability in atherosclerotic hyperfibrinogenemic patients. Atherosclerosis 1988 Jun; 71: 113-9
57. Branchi A, Rovellini A, Sommariva D, et al. Effect of three fibrate derivatives and of two HMG-CoA reductase inhibitors on plasma fibrinogen level in patients with primary hypercholesterolemia. Thromb Haemost 1993 Aug 2; 70: 241-3
58. Tomlinson B, Lee KKC, Say TK, et al. Reduction of coronary heart disease risk factors with bezafibrate treatment in dyslipidaemia [in p. A22] [abstract]. Presented at the 6th International Congress on Cardiovascular Pharmacotherapy, Sydney, 26-29 Feb 1996.
59. Wu Y, Li J, Zuo L, et al. Effect of bezafibrate on fibrinogen binding to platelets in patients with hyperlipidemia [abstract no. 30]. Fibrinolysis 1996; 10 Suppl. 1: 9
60. Sinzinger H, Pirich C, Kondor P, et al. Atherogenic risk reduction in patients with dyslipidaemia. Comparison between bezafibrate and lovastatin. Eur Heart J 1995; 16: 1491-501
61. Specht-Leible N, Schlierf G, Lang PD, et al. Fibrinogen and bezafibrate - a pilot study in patients following percutaneous transluminal coronary angioplasty (PTCA). Clin Hemorheol 1993; 13: 679-85
62. Ishiwata S, Nakanishi S, Nishiyama S, et al. Prevention of restenosis by bezafibrate after successful coronary angioplasty. Coron Artery Dis 1995; 6: 883-9
63. Ernst H, Resch KL. Therapeutic interventions to lower plasma fibrinogen concentration. Eur Heart J 1995; 16 Suppl. A: 47-53
64. Ericsson C-G, Hamsten A, Nilsson J, et al. Angiographic assessment of effects of bezafibrate on progression of coronary artery disease in young male postinfarction patients. Lancet 1996 Mar 30; 346: 849-53
65. Barasch E, Benderly M, Graff E, et al. Plasma fibrinogen levels and their correlates in 6457 coronary heart disease patients. The Bezafibrate Infarction Prevention (BIP) Study. J Clin Epidemiol 1995; 48 (6): 757-65
66. Benderly M, Graff E, Reicher-Reiss H, et al. Fibrinogen is a predictor of mortality in coronary heart disease patients. Art Thrombosis Vasc Biol 1996 Mar; 16 (3): 351-6
67. Mikhailidis DP, Mathur S, Barradas MA, et al. Bezafibrate retard in type II diabetic patients: effects on hemostasis and glucose homeostasis. J Cardiovasc Pharmacol 1990; 16 Suppl. 9: S26-29
68. Durrington PN, Winocour PH, Bhatnagar D. Bezafibrate retard in patients with insulin-dependent diabetes: effect on serum lipoproteins, fibrinogen, and glycemic control. J Cardiovasc Pharmacol 1990; 16 Suppl. 9: 30-4
69. Niort G, Cavallero G, Cassader M, et al. The use of bezafibrate in the reduction of lipid and pro-thrombotic cardiovascular risk factors in non-insulin dependent diabetes mellilus. Diabetes Nutr Metab 1995; 8 (4): 226-33
70. Niort G, Cassader M, Gambino R, et al. Comparison of the effects of bezafibrate and acipimox on the lipid pattern and plasma fibrinogen in hyperlipidaemic type 2 (non-insulin-dependent) diabetic patients. Diabete Metab 1992 May-Jun; 18: 221-8
71. Schernthaner G, Bauer I, Vukovich T, et al. The effect of benzafibrate or lovastatin on the hemostatic system, dyslipidemia and diabetes control in type-2 diabetes [abstract]. Atherosclerosis 1995 Jun; 115 Suppl.: S52
72. Bo M, Bonino F, Neirotti M, et al. Hemorheologic and coagulative pattern in hypercholesterolemic subjects treated with lipid-lowering drugs. Angiology 1991 Feb; 42: 106-13
73. Binsack R, Stagemeier K, Doerge L, et al. Effect of bezafibrate on apolipoprotein B, fibrinogen and two other secretory proteins of human hepatoma HEPG2 cells [abstract]. Clin Hemorheol 1993; 13 (3) Special Issue: 290
74. Miller GJ, Martin JC, Mitropoulos KA, et al. Plasma factor VII is activated by postprandial triglyceridaemia irrespective of dietary fat composition. Atherosclerosis 1991; 86: 163-71
75. Mitropooulos KA, Miller GJ, Reeves BEA, et al. Factor VII coagulant activity is strongly associated with the plasma concentration of large lipoprotein particles in middle-aged men. Atherosclerosis 1989; 76: 203-8
76. Waysbort J, Schwartz S, Brunner D. Effect of bezafibrate on lipids, lipoproteins, apolipoproteins and platelet aggregation in hypertriglyceridemic patients. Arzneimittel Forschung 1994 Nov; 44: 1217-22
77. Keber D, Cevc M, Keber I. Increased PAI-1 antigen after short term treatment with gemfibrozil as opposed to unchanged levels after bezafibrate and lovastatin [abstract]. Thromb Haemost 1991 Jun 5; 65 (6): 1276
78. Alberti KGMM, Jones IR, Laker MF, et al. Effect of bezafibrate on metabolic profiles in non-insulin-dependent diabetes mellitus. J Cardiovasc Pharmacol 1990; 16 Suppl. 9: S21-25
79. Ohsawa K, Nagai Y, Takazakura E, et al. Lowering of plasma glucose concentrations with bezafibrate in NIDDM with secondary sulfonylurea failure [abstract]. In: 15th International Diabetes Federation Congress. :, 1994: 427
80. Rovellini A, Sommariva D, Branchi A, et al. Effects of slow release bezafibrate on the lipid pattern and on blood glucose of type-2 diabetic patients with hyperlipidaemia. Pharmacol Res 1992 Apr; 25: 237-45
81. Sinzinger H, Virgolini I, Kudlacek P. Effect of bezafibrate on infarction risk (SPIRIT) in isolated hypercholesterolemia and mixed hyperlipidemia: an open multicenter trial [in German]. Wien Klin Wochenschr 1991; 103 (13): 381-7
82. Stewart MW, Dyer RG, Alberti KGMM, et al. The effects of lipid lowering drugs on metabolic control and lipoprotein composition in type 2 diabetic patients with mild hyperlipidaemia. Diabetic Med 1995 Mar; 12: 250-7
83. Onuma T, Tsutsui M, Boku A, et al. Effects of bezafibrate on abnormal lipoprotein metabolism and glucose tolerance in patients with non-insulin-dependent diabetes mellitus. Curr Ther Res 1992 Mar; 51: 439-47
84. Riccardi G, Genovese S, Saldalamacchia G, et al. Effects of bezafibrate on insulin secretion and peripheral insulin sensitivity in hyperlipidemic patients with and without diabetes. Atherosclerosis 1989 Feb; 75: 175-81
85. Chiba T, Fukuda M, Sugimura K, et al. Clinical effect of bezafibrate on hyperlipidemia complicated with non-insulin dependent diabetes mellitus [in Japanese]. Rinsho Iyaku 1993; 9 (7): 1693-703
86. Smud R, Sermukslis B. Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia. Curr Med Res Opin 1987; 10: 612-24
87. Onuma T, Matsui J, Tsutsui M, et al. A case of insulin-independent diabetes mellitus decreasing in the dose of oral hypoglycemic agent (glibenclamide) after administration of bezafibrate [in Japanese]. Rinsho Iyaku 1991; 7 (12): 2841-7
88. Winocour PH, Durrington PN, Bhatagnar D, et al. The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in Type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia. Atherosclerosis 1992 Mar; 93: 83-94
89. Karhapää P, Uusitupa M, Voutilainen E, et al. Effects of bezafibrate on insulin sensitivity and glucose tolerance in subjects with combined hyperlipidemia. Clin Pharmacol Ther 1992 Dec; 52: 620-6
90. Inoue I, Takahashi K, Katayama S, et al. Improvement of glucose tolerance by bezafibrate in non-obese patients with hyperlipidemia and impaired glucose tolerance. Diabetes Res Clin Pract 1994 Oct; 25: 199-205
91. Gandini R, Assereto R, Castoldi D, et al. Normal and slow-release formulations of bezafibrate: a comparative pharmacokinetic study in man. Int J Clin Pharmacol Res 1987; 7: 149-55
92. Vens-Cappell B, Hilgenstock C, Gellert M, et al. Comparison of the pharmacokinetic profiles of a quick and a sustained release bezafibrate formulation. First communication: single-dose application [in German]. Arzneimittel Forschung 1993 Mar; 43: 346-50
93. Vens-Cappell B, Berndt P, Hilgenstock C, et al. Comparison of the pharmacokinetic profiles of a quick and a sustained release bezafibrate formulation. Second communication: multiple-dose application and chronopharmacokinetics [in German]. Arzneimittel Forschung 1993 Mar; 43: 351-6
94. Abshagen U, Spörl-Radun S, Marinow J. Steady-state kinetics of bezafibrate and clofibrate in healthy female volunteers. Eur J Clin Pharmacol 1980; 17: 305-8
95. Abshagen U, Bablok W, Koch K, et al. Disposition pharmacokinetics of bezafibrate in man. Eur J Clin Pharmacol 1979; 16: 31-8
96. Ledermann H, Kaufmann B. Comparative pharmacokinetics of 400mg bezafibrate after a single oral administration of a new slow-release preparation and the currently available commercial form. J Int Med Res 1981; 9: 516-20
97. Williams AJ, Walls J. The pharmacokinetics of bezafibrate in patients undergoing continuous ambulatory peritoneal dialysis (CAPD). Peritoneal Dialysis Bulletin 1986; 6: 69-71
98. Neugebauer G, Platt D, Vömel T, et al. Steady-state kinetics of bezafibrate retard in hyperlipidemic geriatric patients. Klin Wochenschr 1988 Mar 15; 66: 250-6
99. Pyörälä K, De Backer G, Graham I, et al. Prevention of coronary heart disease in clinical practice: recommendation of the Task Force of the European Society of Cardiology, European Atherosclerosis Society and European Society of Hypertension. Atherosclerosis 1994; 110: 121-61
100. Betteridge DJ, Dodson PM, Durrington PN, et al. Management of hyperlipidaemia: guidelines of the British Hyperlipidaemia Association. Postgrad Med J 1993 May; 69: 359-69
101. Császár A, Karádi I, Köszegi G, et al. Long lasting efficacy of Bezalip Retard on the regulation of lipid levels after discontinuation of administration in patients with hyperlipoproteinemia. Klin Wochenschr 1990; 68 Suppl. 22: 96-8
102. Bertolami MC, Faludi AA, Sadoyama R, et al. Study of the efficacy and tolerance of bezafibrate retard in the treatment of primary hyperlipidemia [in Portuguese]. Rev Bras Med 1991 Sep; 48: 631-6
103. Nishi M, Sowa R, Sanke T, et al. Effect of bezafibrate on serum lipid concentrations [in Japanese]. Rinsholyaku 1995; 11 (6): 1285-96
104. Saito N. Clinical effect of Bezatol (Rm) SR on hypertriglyceridemia [in Japanese]. Shinryo to Shinyaku 1992; 29 (8): 1901-10
105. Bradford RH, Goldberg AC, Schonfeld G. Double-blind comparison of bezafibrate versus placebo in male volunteers with hyperlipoproteinemia. Atherosclerosis 1992 Jan; 92: 31-40
106. Cesarone MR, Belcaro G, Laurora G, et al. 4-Year progression of early arterial wall lesions in asymptomatic hyperlipidemic subjects treated with bezafibrate. Int J Angiol 1995; 4 (1): 51-4
107. Bonner G, Steinmetz A, Arntz HR, et al. Pravastatin and bezafibrate, comparison of the one year results [abstract]. Cardiovasc Drugs Ther 1991 Apr; 5 Suppl. 3: 357
108. Arsenio L, Rossi A. Efficacy of blood lipid normalization and tolerance in dyslipidemic patients treated for 18 months with fibric acid derivatives [in Italian]. Clin Ter 1989 Dec 31; 131: 403-12
109. Bittolo Bon G, Soldan S, Cazzolato G, et al. Efficacy and tolerability of bezafibrate slow-release formulation vs fenofibrate in the treatment of patients with type IIb hyperlipoproteinaemia. Curr Ther Res 1990; 47 (4): 735-42
110. Kremer P, Marowski C, Jones C, et al. Therapeutic effects of bezafibrate and gemfibrozil in hyperlipoproteinaemia type IIa and IIb. Curr Med Res Opin 1989; 11: 293-303
111. Betteridge DJ, O'Bryan-Tear G, Tomlinson MJ. A comparison of ciprofibrate and sustained release bezafibrate in patients with type II hyperlipidaemia [abstract]. Atherosclerosis 1995 Jun; 115 Suppl.: 97
112. Bastow MD, Durrington PN, Ishola M. Hypertriglyceridemia and hyperuricemia: effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial. Metabolism 1988 Mar; 37: 217-20
113. Smith DHG, Neutel JM, Jankelow D, et al. Bezafibrate and simvastatin (MK-733) in the treatment of primary hypercholesterolaemia. S Afr Med J 1990 May 19; 77: 500-3
114. Forti N. Atherogenic lipid fraction plasma level reductions induced by simvastatin and bezafibrate. Brazilian multicenter study [in Portuguese]. Arq Bras Cardiol 1993 Jun; 60: 437-44
115. Bruckert E, Truffert J, De Gennes JL. Comparison of the efficacy and tolerance of simvastatin and bezafibrate in the treatment of hypercholesterolemia [in French]. Ann Med Interne Paris 1991; 142: 505-10
116. Arntz H-R, Bönner G, Kikis D, et al. Efficacy of pravastatin and bezafibrate in primary hypercholesterolaemia [in German]. Dtsch Med Wochenschr 1991 Jan 4; 116: 7-12
117. Schumacher M, Eber B, Silberbauer K, et al. Efficacy, safety and tolerability of lovastatin and bezafibrate retard in patients with hypercholesterolemia. Acta Med Austriaca 1992; 19 (5): 140-4
118. Giannini SD. Comparison of lipid-lowering effects of lovastatin and bezafibrate in patients with primary hypercholesterolemia. The Brazilian multicenter study [in Portuguese]. Rev Bras Med 1990 May; 47: 177-84
119. Beil FU, Beisiegel U, Schrameyer-Wernecke A, et al. Lovastatin versus bezafibrate: effects on lipoproteins and urinary mevalonate. Atherosclerosis 1992 Dec; 97 Suppl.: S49-57
120. Fanghänel G, Espinosa J, Olivares D, et al. Open-label study to assess the efficacy, safety, and tolerability of fluvastatin versus bezafibrate for hypercholesterolemia. Am J Cardiol 1995 Jul 13; 76: 57A-61A
121. Steinhagen-Thiessen E, Muller S, Holler HD, et al. Effect of bezafibrate and colestyramine in patients with primary hypercholesterolemia. Arzneimittel Forschung 1987 Jun; 37: 726-8
122. Moreno JP, González G. Comparative study of bezafibrate and probucol in hyperlipidaemia. Curr Med Res Opin 1989 May; 11: 523-32
123. Holzgartner H, Schmidt U, Kuhn U. Comparison of the efficacy and tolerance of a garlic preparation vs. bezafibrate. Arzneimittel Forschung 1992 Dec; 42: 1473-7
124. Yeshurun D, Abukarshin R, Elias N, et al. Treatment of severe, resistant familial combined hyperlipidemia with a bezafibrate-lovastatin combination. Clin Ther 1993 Mar-Apr; 15: 355-63
125. Testa I, Polenta M, Monteburini T, et al. Combined hypolipidaemic treatment of obesity with severe dyslipidaemia [in French]. Presse Med 1995 Jan 7; 24: 10-4
126. Eliav O, Schurr D, Pfister P, et al. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia. Am J Cardiol 1995 Jul 13; 76: 76-9
127. Ageta M, Matsuo T, Kumagai H. Combined therapy of fluvastatin, a new HMG-CoA reductase inhibitor, and bezafibrate in hyperlipidemic patients with type IIb. Rinsho Iyaku 1995; 3 (4) Suppl. 2: 191-209
128. Deslypere JP. Addition of fibrates to simvastatin therapy in hyperlipidaemic patients. Atherosclerosis 1992 Dec; 97 Suppl.: S67-71
129. Kehely A, MacMahon M, Barbir M, et al. Combined bezafibrate and simvastatin treatment for mixed hyperlipidaemia. Q J Med 1995; 88: 412-27
130. Hutchesson ACJ, Moran A, Jones AF. Dual bezafibrate-simvastatin therapy for combined hyperlipidaemia. J Clin Pharm Ther 1994 Dec; 19: 387-9
131. Lintott CJ, Scott RS, Sharpe DN, et al. Treatment of primary hypercholesterolaemia with simvastatin. New Zealand multicentre evaluation. Med J Aust 1991 Oct 7; 155: 433-6
132. Leitersdorf E, Muratti EN, Eliav O, et al. Efficacy and safety of a combination fluvastatin-bezafibrate treatment for familial hypercholesterolemia: comparative analysis with a fluvastatin-cholestyramine combination. Am J Med 1994 May; 96: 401-7
133. Leitersdorf E, Muratti EN, Eliav O, et al. Efficacy and safety of triple therapy (fluvastatin-bezafibrate-cholestyramine) for severe familial hypercholesterolemia. Am J Cardiol 1995 Jul 13; 76: 84-8
134. Fischer S, Hanefeld M, Lang PD, et al. Efficacy of a combined bezafibrate retard-colestyramine treatment in patients with hypercholesterolemia. Arzneimittel Forschung 1990 Apr; 40 Suppl. 1: 469-72
135. Curtis LD, Dickson AC, Ling KL, et al. Combination treatment with cholestyramine and bezafibrate for heterozygous familial hypercholesterolaemia. BMJ 1988 Jul 16; 297: 173-5
136. Arnon R, Sebayek E, Eisenberg S. Disparate effects of a triglyceride lowering diet and of bezafibrate on the HDL system: a study in patients with hypertriglyceridaemia and low HDL-cholesterol levels. Eur J Clin Invest 1993 Aug; 23: 492-8
137. Luria MH, Sapoznikov D. Raising HDL cholesterol with low-dose nicotinic acid and bezafibrate: preliminary experience. Postgrad Med J 1993 Apr; 69: 296-9
138. Harris C, Stirling G, Lloyd J, et al. Qualitative diabetic lipoprotein change: post-prandial profile & bezafibrate therapy [abslract]. Atherosclerosis 1995 Jun; 115 Suppl.: S52
139. Niort G, Gambino R, Cassader M, et al. Bezafibrate affects lipid, lipo- and apolipoprotein pattern in non-insulin-dependent diabetic patients. Horm Metab Res 1993 Jul; 25: 372-4
140. Seviour PW, Teal TK, Richmond W, et al. Serum lipids, lipoproteins and macrovascular disease in non-insulin-dependent diabetics: a possible new approach to prevention. Diabet Med 1988 Mar; 5: 166-71
141. Mathur S, Barradas MA, Mikhailidis DP, et al. The effect of a slow release formulation of bezafibrate on lipids, glucose homeostasis, platelets and fibrinogen in type II diabetics: a pilot study. Diabetes Res 1990 Jul; 14: 133-8
142. Pelegri A, Romero R, Senti M, et al. Effect of bezafibrate on lipoprotein(a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis. Nephrol Dial Transplant 1992; 7 (7): 623-6
143. Feussner G, Bommer J, Ziegler R. Severe type III hyperlipoproteinemia in two patients maintained on chronic hemodialysis. Klin Wochenschr 1990 Jan 19; 68: 65-70
144. Chan MK. Sustained-release bezafibrate corrects lipid abnormalities in patients on continuous ambulatory peritoneal dialysis. Nephron 1990 Sep; 56: 56-61
145. Goldhourt U, Behar S, Reícher-Reiss H, et al. Rationale and design of a secondary prevention trial of increasing serum high-density lipoprotein cholesterol and reducing triglycerides in patients with clinically manifest atherosclerotic heart disease (the Bezafibrate Infarction Prevention Trial). Am J Cardiol 1993 Apr 15; 71: 909-15
146. De Faire U, Ericsson C-G,. Hamsten A, et al. Design features of a five-year bezafibrate coronary atherosclerosis intervention trial (BECAIT). Drugs in Exper Clin Res 1995; 21 (3): 104-24
147. Hidalgo L, Zambrana JL, Blanco-Molina A, et al. Lovastatin versus bezafibrate for hyperlipemia treatment after heart transplantation. J Heart Lung Transplant 1995; 14: 461-7
148. Seiler C, Suter TM, Hess OM. Exercise-induced vasomotion of angiographically normal and stenotic coronary arteries improves after cholesterol-lowering drug therapy with bezafibrate. J Am Coll Cardiol 1995; 26 (7): 1615-22
149. Reckless JPD. Cost implications of lipid-lowering treatments. PharmacoEconomics 1994 Oct; 6: 310-23
150. Bergemann R, Brandt A, Siegrist W. Cost-effectiveness study of a lipid-lowering therapy in hyperlipoproteinaemia type IIb and type IV (Frederickson). PharmacoEconomics 1993 Feb; 3: 131-9
151. Turpin G. Etude extensive d'un hypolipidémiant le bézafibrate en médecine génèrale. Gaz Med 1986; 93: 57-63
152. Serrano G, Fortea JM, Latasa JM, et al. Photosensitivity induced by fibric acid derivatives and its relation to photocontact dermatitis to ketoprofen. J Am Acad Dermatol 1992 Aug; 27: 204-8
153. Ariad S, Hechtlinger V. Bezafibrate-induced neutropenia. Eur J Haematol 1993 Mar; 50: 179
154. Ellis CJ, Wallis WE, Caruana M. Peripheral neuropathy with bezafibrate. BMJ 1944 Oct 8; 309: 929
155. Toubi E, Seligmann H, Golan TD. Bezalip-induced anaphylaxis. Ann Allergy, Asthma Immunol 1995 Oct; 75: 370
156. Vita G, Toscano A, Mileto G, et al. Bezafibrate-induced myopathy: no evidence for defects in muscle metabolism. Eur Neurol 1993 Mar-Apr; 33: 168-72
157. Kanterewicz E, Sanmartí R, Riba J, et al. Bezafibrate induced rhabdomyolysis. Ann Rheum Dis 1992 Apr; 51: 536-8
158. Venzano C, Cordi GC, Corsi L, et al. Rhahdomyolysis with acute renal failure due to bezafibrate and furosemide [in Italian]. Minerva Med 1990 Dec; 81: 909-11
159. Malnick SDH, Badir A, Landau Z. Bezafibrate-induced rhabdomyolysis. DICP 1991 Jul-Aug; 25: 869-70
160. Bedani PL, Perini L, Gilli P. Acute rhabdomyolysis and hemoglobin reduction after bezafibrate overdose in hyperlipidemic patients on hemodialysis. Nephron 1994; 68: 512-3
161. Panuccio V, Enia G, Parlongo S, et al. Severe rhabdomyolysis induced by a retard formulation of bezafibrate in a CAPD patient [letter]. Nephron 1996; 73: 736
162. Górriz JL, Sancho A, Alcoy E, et al. Rhabdomyolysis and acute renal failure associated with bezafibrate treatment. Nephrol Dial Transplant 1995; 10: 2371-82
163. Ismail HM, Al-Idrisi Facharzt HY, Al-Kalaf J. Combined myo-neuro-toxicity by bezafibrate. Saudi Med J 1993 Jan; 14: 86-7
164. Lipkin GW, Tomson CRV. Severe reversible renal failure with bezafibrate. Lancet 1993 Feb 6; 341: 371
165. Jespersen B, Tvedegaard E. Bezafibrate induced reduction of renal function in a renal transplant recipient. Nephrol Dial Transplant 1995; 10: 702-3
166. Newman TB, Hulley SB. Carcinogenicity of lipid-lowering drugs. JAMA 1996 Jan 3; 275: 55-60
167. Dalen JE, Dalton WS. Does lowering cholesterol cause cancer? JAMA 1996 Jan 3; 275: 67-9
168. Eriksson M, Angelin B. Bezafibrate therapy and biliary lipids: effects of short-term and long-term treatment in patients with various forms of hyperlipoproteinaemia. Eur J Clin Invest 1987 Oct; 17: 396-401
169. Raedseh R, Plachky J, Wolf N, et al. Biliary lipids, lithogenic index and biliary drug concentrations during etofibrate and bezafibrate treatment. Eur J Drug Metab Pharmacokinet 1995 Apr-Jun; 20: 113-8
170. Armstrong K, Kelly AJ. Bezafibrate and cholelithiasis. Eur J Gastroenterol Hepatol 1993 Aug; 5: 665
171. Blum A, Livneh A, Seligmann H, et al. Severe gastrointestinal bleeding induced by a probable hydroxycoumarin-bezafibrate interaction. Isr J Med Sci 1992 Jan; 28: 47-9
172. Bezafibrate prescribing information. In: Reynolds JEF, editor. Martindale. The extra pharmacopoeia. 30th ed. London: The Pharmaceutical Press, 1993: 984
173. Hirai M, Tatuso E, Sakurai M, et al. Elevated blood concentrations of cyclosporine and kidney failure after bezafibrate in renal graft recipient. Ann Pharmacother 1996 Jul/Aug; 30: 883-4
174. Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia. N Engl J Med 1987 Nov 12; 317 (20): 1237-45
175. Huttunen JK, Heinonen OP, Manninen V, et al. The Helsinki Heart Study: an 8.5-year safety and mortality follow-up. J Intern Med 1994 Jan; 235: 31-9
176. The Lipid Research Clinics Coronary Primary Prevention trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984; 251: 351-64
177. The Lipid Research Clinics Coronary Primary Prevention trial results. II.
178. Hodis HN, Mack WJ. Triglyceride-rich lipoproteins and the progression of coronary artery disease. Cur Opin Lipidol 1995; 6: 209-14
179. Gianturco SH, Bradley WA. Triglyceride-rich lipoproteins and their role in atherogenesis. Cur Opin Lipidol 1991; 2: 324-8
180. Austin MA, Goto Y, Lenfant C, et al. The hypertriglyceridemias: risk and management. 5. Epidemiology. Am J Cardiol 1991 July 24; 68 (3): 22A-5A
181. Nafziger AN. Clinical relevance of reducing triglycerides. Implications for ischaemic heart disease treatment. Drugs 1994 July; 48 (1); 1-8
182. Avogaro P, Ghiselli G, Soldan S, et al. Relationship of triglycerides and HDL cholesterol in hypertriglyceridemia. Atherosclerosis 1992 Jan; 92: 79-86
183. Triglycerides feature prominently in Lipid Metabolism meeting. Pharm Bus News 1995 Nov 23: 32-4
184. Schaefer EJ, Lamon-Fava S, Jenner JL, et al. Lipoprotein(a) levels and risk of coronary heart disease in men. JAMA 1994 Apr 6; 271 (13): 999-1003
185. Hogg CF, Zuhrie SR, Meade TW. Trial of bezafibrate in lower extremity arterial disease: pilot study results. Thromb Haemost 1995; 73 (6): 1328
186. Merrin PK, Elkeles RS. Treatment of diabetes: the effect on serum lipids and lipoproteins. Postgrad Med J 1991 Oct; 67: 931-7
187. Modan B, Assmann G, Bauer P, et al. Statement of the International Review and Advisory Board of the Bezafibrate Infarction Prevention Study after its meeting on May 31, 1995, in Charlottesville, Va. Circulation 1995 Oct 1; 92: 1675